# A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA

> **NCT03124498** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chuan An Biotechnology Co., Ltd.** · enrollment: 55 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** CIK Cell

## Key facts

- **NCT ID:** NCT03124498
- **Lead sponsor:** Chuan An Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03124498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03124498, "A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03124498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*